Home › Encyclopedia › Thymosin Alpha-1: Research Status And Trial Data
Research / Unapproved

Thymosin Alpha-1: Research Status And Trial Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC129H215N33O55
Molecular weight3108.3 g/mol
Registered trials65
PubChem CID16130571

What Thymosin Alpha-1 Is

Thymosin alpha-1 is a synthetic peptide (molecular formula C129H215N33O55, molecular weight approximately 3,108 daltons, PubChem CID 16130571) studied in laboratory and clinical research settings. It has no FDA-approved label, brand name, or approved indication in the United States. Any use outside a registered clinical trial falls outside its current regulatory status as an unapproved research compound.

Trial Footprint

Across public registries, thymosin alpha-1 appears in 65 registered clinical trials to date. One completed trial examined its use in patients with sepsis, and a separate completed study looked at a related hepatitis B treatment approach. Another trial, now listed with unknown status, paired thymosin alpha-1 with standard maintenance therapy in patients with metastatic non-small cell lung cancer who carry wild-type EGFR. These records describe study design and status only, not proven benefit or approved use.

FAQ

Is thymosin alpha-1 FDA-approved?
No. Thymosin alpha-1 has no FDA-approved label, brand name, or approved indication. It is classified as an unapproved research compound studied in clinical trials.
What conditions has thymosin alpha-1 been studied for?
Public trial records show research involving sepsis, hepatitis B infection, and metastatic non-small cell lung cancer with wild-type EGFR. These are areas of investigation, not confirmed or approved uses.
How many clinical trials involve thymosin alpha-1?
Registries list 65 clinical trials involving thymosin alpha-1. These trials vary in design, condition studied, and completion status.
What is thymosin alpha-1 chemically?
It is a synthetic peptide with the molecular formula C129H215N33O55 and a molecular weight of about 3,108 daltons, identified in PubChem under CID 16130571.
Has thymosin alpha-1 been shown to work for sepsis or cancer?
One sepsis trial and one lung cancer trial involving thymosin alpha-1 are recorded as completed or ongoing, but this monograph does not draw conclusions about efficacy. Findings should be reviewed directly from the primary trial data.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov trial sample ClinicalTrials.gov registry count

Updated 2026-08-03